Analyst Joseph Stringer of Needham maintained a Buy rating on Gilead Sciences, boosting the price target to $170.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Stringer has given his Buy rating due to a combination of factors tied to Gilead’s stronger‑than‑expected financial and operational performance. The company’s fourth‑quarter results exceeded both his and the Street’s revenue and EPS forecasts, largely on the back of continued momentum in its HIV portfolio, and its initial 2026 revenue outlook aligns well with market expectations while still offering room for upside.
Moreover, he points to the durability and growth of the HIV business, including steady mid‑single‑digit annual expansion and a rapidly growing PrEP segment, as key drivers of future cash flow. Combined with management’s cost control efforts and improving operating margins, these dynamics reinforce his conviction that Gilead’s earnings power is underappreciated at current levels, supporting a Buy rating and a higher price target.
In another report released today, BMO Capital also reiterated a Buy rating on the stock with a $160.00 price target.